Response to Vocational Rehabilitation during Treatment with First- or Second-Generation Antipsychotics

Psychiatric Services

Volumn 55, Issue 1, 2004, Pages 59-66

  Bond, Gary R ^a   Kim, Hea Won ^b   Meyer, Piper S ^c   Gibson, P Joseph ^d   Tunis, Sandra ^e   Evans, Jovier D ^a   Lysaker, Paul ^f   McCoy, Marion L ^g   Dincin, Jerry ^h   Xie, Haiyi ⁱ  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF SOCIAL WORK   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Marion County Health Department   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g WESTAT   (United States)

^h Thresholds   (United States)

ⁱ DARTMOUTH PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; EMPLOYMENT; FEMALE; HUMAN; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PSYCHOSIS; REHABILITATION CENTER; SCHIZOPHRENIA; TREATMENT INDICATION; VOCATIONAL GUIDANCE; VOCATIONAL REHABILITATION;

ADULT; ANTIPSYCHOTIC AGENTS; CHICAGO; FEMALE; HUMANS; INDIANA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; REHABILITATION, VOCATIONAL; SCHIZOPHRENIA;

EID: 9144227156     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.55.1.59     Document Type: Article

References (47)

1. Mueser KT, Salyers MP, Mueser PR: A prospective analysis of work in schizophrenia. Schizophrenia Bulletin 27:281-296, 2001
2. Bond GR: Principles of the individual placement and support model: empirical support. Psychiatric Rehabilitation Journal 22:11-23, 1998
3. Bond GR, Drake RE, Mueser KT, et al: An update on supported employment for people with severe mental illness. Psychiatric Services 48:335-346, 1997
4. Bond GR: Vocational rehabilitation in Handbook of Psychiatric Rehabilitation. Edited by Liberman RP. New York, Macmillan, 1992
5. Bond GR, Drake RE, Becker DR, et al: Effectiveness of psychiatric rehabilitation approaches for employment of people with severe mental illness. Journal of Disability Policy Studies 10:18-52, 1999
6. Bond GR, Becker DR, Drake RE, et al: Implementing supported employment as an evidence-based practice. Psychiatric Services 52:313-322, 2001
7. Lehman AF: Vocational rehabilitation in schizophrenia. Schizophrenia Bulletin 21:645-656, 1995
8. Bond GR, Meyer PS: The role of medications in the employment of people with schizophrenia. Journal of Rehabilitation 65 (4):9-16, 1999
9. Corrigan PW, Penn DL: The effects of antipsychotic and antiparkinsonian medication of psychosocial skill learning. Clinical Psychology: Science and Practice 2:251-262, 1995
10. Hogarty G, Goldberg S: Drug and sociotherapy in the aftercare of schizophrenia patients: one-year relapse rates. Archives of General Psychiatry 28:54-64, 1973
11. Schade ML, Corrigan PW, Liberman RP: Prescriptive rehabilitation for severely disabled psychiatric patients. New Directions for Mental Health Services 45:3-7, 1990
12. Schwarzkopf SB, Crilly JF, Silverstein SM: Therapeutic synergism: optimal pharmacotherapy and psychiatric rehabilitation to nhance functional outcome in schizophrenia. Psychiatric Rehabilitation Skills 3:124-147, 1999
13. Weiden PJ, Aquila R, Standard J: Atypical antipsychotic drugs and long-term outcome in schizophrenia. Journal of Clinical Psychiatry 57(suppl 11):53-60, 1996
14. Casey, DE: Side effect profiles of new antipsychotics agents. Journal of Clinical Psychiatry 57(Suppl 11):40-45, 1996
15. Geddes J, Freemantle N, Harrison P, et al: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal 321:1371-1376, 2000
16. Leucht S, Pitschel-Walz G, Abraham D, et al: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35:51-68, 1999
17. Moller HJ, Muller H, Borison RL, et al: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. European Archives of Psychiatry and Clinical Neuroscience 245:45-49, 1995
18. Rabinowitz J, Bromet EJ, Davidson M: Short-report: comparison of patients satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study. Schizophrenia Bulletin 27:597-600, 2001
19. Tamminga CA: The promise of new drugs for schizophrenia treatment. Canadian Journal of Psychiatry 42:265-273, 1997
20. Tollefson GD, Beasley CM Jr, Tran PV, et al: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 154:457-465, 1997
21. Franz M, Lis S, Phiddemann K, et al: Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. British Journal of Psychiatry 170:422-425, 1997
22. Meltzer HY, Burnett S, Bastani B, et al: Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry 41:892-897, 1990
23. Meltzer HY, Cola P, Way L: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry 150:1630-1638, 1993
24. Tunis SL, Johnstone BM, Gibson J, et al: Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. Journal of Clinical Psychiatry 60(suppl 19):38-45, 1999
25. Rosenheck R, Tekell J, Peters J, et al: Does participation in psychosocial treatment augment the benefit of clozapine? Archives of General Psychiatry 55:618-625, 1998
26. Stroup TS, McEvoy JP, Swartz MS, et al: The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29:15-31, 2003
27. Lindström LH, Lundberg T: Long-term effect on outcome of clozapine in chronic therapy-resistant schizophrenic patients. European Psychiatry 12(suppl 5):353s-355s, 1997
28. Littrell K: Maximizing schizophrenia treatment outcomes: a model for integration. Psychiatric Rehabilitation Journal 19:75-77, 1995
29. Noordsy D, O'Keefe C: Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a CMHC setting. Journal of Clinical Psychiatry 60(suppl 19):47-51, 1999
30. Noordsy DL, O'Keefe C, Mueser KT, et al: Twelve-month outcomes for patients switched to olanzapine in community psychiatric care. Poster presented at the Institute on Psychiatric Services, Philadelphia, Oct 25-29, 2000
31. Noordsy D, O'Keefe C, Mueser KT, et al: Six-month outcomes for patients who switched to olanzapine treatment. Psychiatric Services 52:501-507, 2001
32. McGurk SR, Meltzer HY: The role of cognition in vocational functioning in schizophrenia. Schizophrenia Research 45:175-184, 2000
33. Meyer PS, Bond GR, Tunis SL, et al: Companion between the effects of atypical and traditional antipsychotics on work status for clients in a psychiatric rehabilitation program. Journal of Clinical Psychiatry 63:108-116, 2002
34. Hamilton SH, Edgell ET, Revicki DA, et al: Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample. International Clinical Psychopharmacology 15:245-255, 2000
35. Weiden PJ, Aquila R, Kinon BJ, et al: Effectiveness of olanzapine upon psychiatric and vocational rehabilitation outcomes. Poster presented at the Institute on Psychiatric Services, New Orleans, Oct 1999
36. Bond GR, Kim HW, Meyer P, et al: Longitudinal impact of second generation antipsychotics and psychiatric rehabilitation: final report submitted to Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company. Indianapolis, Ind, Indiana University-Purdue University Indianapolis, 2002
37. Koop J, Rollins AL, Bond GR, et al: Development of the DPA Fidelity Scale: using fidelity to define an existing vocational model. Psychiatric Rehabilitation Journal, in press
38. Vogler KM: A fidelity study of the Indiana Supported Employment Model for individuals with severe mental illness in Psychology. Indianapolis, Ind, Indiana University-Purdue University Indianapolis, 1998
39. CIDI-Auto Version 2.1: Administrator's Guide and Reference. St. Louis, Training and Reference Centre for the World Health Organization CIDI, 1997
40. First MB, Spitger RL, Gibbon M, et al: Structured Clinical Interview for Axis I DSM-IV Disorders-Patient Edition (SCID-I/P, Version 2.0). New York, Biometric Research Department, New York State Psychiatric Institute, 1994
41. Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13:261-276, 1987
42. Bell MD, Lysaker PH, Beam-Goulet JL, et al: Five-component model of schizophrenia: assessing the factorial invariance of the Positive and Negative Syndrome Scale. Psychiatry Research 52:295-303, 1994
43. Cook J, Razzano L: Vocational rehabilitation for persons with schizophrenia: recent research and implications for practice. Schizophrenia Bulletin 26:87-103, 2000
44. Littell R, Milliken G, Stroup W, et al: SAS System for Mixed Models. Cary, NC, SAS Institute, Inc., 1996
45. Lehman AF, Schizophrenia PORT Team: Schizophrenia Patient Outcomes Treatment Team (PORT) Treatment Recommendations: 2003 Update. Baltimore, University of Maryland School of Medicine/Johns Hopkins University Center for Research on Services for Severe Mental Illness, 2003
46. Wang PS, West JC, Tanielan T, et al: Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophrenia Bulletin 26:451-457, 2000
47. Mellman TA, Miller AL, Weissman EM, et al: Evidence-based pharmacologic treatment for people with severe mental illness: A focus on guidelines and algorithms. Psychiatric Services 52:619-625, 2001